JP2023543439A5 - - Google Patents
Info
- Publication number
- JP2023543439A5 JP2023543439A5 JP2023518416A JP2023518416A JP2023543439A5 JP 2023543439 A5 JP2023543439 A5 JP 2023543439A5 JP 2023518416 A JP2023518416 A JP 2023518416A JP 2023518416 A JP2023518416 A JP 2023518416A JP 2023543439 A5 JP2023543439 A5 JP 2023543439A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- human patient
- compound
- muscular dystrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081073P | 2020-09-21 | 2020-09-21 | |
| US63/081,073 | 2020-09-21 | ||
| US202163195473P | 2021-06-01 | 2021-06-01 | |
| US63/195,473 | 2021-06-01 | ||
| US202163214908P | 2021-06-25 | 2021-06-25 | |
| US63/214,908 | 2021-06-25 | ||
| PCT/US2021/051274 WO2022061287A1 (en) | 2020-09-21 | 2021-09-21 | TREATMENT OF NF-κB-MEDIATED DISEASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543439A JP2023543439A (ja) | 2023-10-16 |
| JP2023543439A5 true JP2023543439A5 (https=) | 2024-10-01 |
Family
ID=80776432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518416A Pending JP2023543439A (ja) | 2020-09-21 | 2021-09-21 | ＮＦ－κＢ媒介疾患の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220184098A1 (https=) |
| EP (1) | EP4213855A4 (https=) |
| JP (1) | JP2023543439A (https=) |
| KR (1) | KR20230092905A (https=) |
| AU (1) | AU2021343534A1 (https=) |
| CA (1) | CA3170698A1 (https=) |
| IL (1) | IL301500A (https=) |
| MX (1) | MX2023003258A (https=) |
| WO (1) | WO2022061287A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4436583A4 (en) * | 2021-11-22 | 2025-04-02 | ReveraGen BioPharma, Inc. | TREATMENT OF NF-kB-MEDIATED DISEASE |
| WO2025199347A1 (en) * | 2024-03-21 | 2025-09-25 | Reveragen Biopharma, Inc. | Treatment of glomerulonephritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006279325B2 (en) * | 2005-08-18 | 2013-06-27 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| CA2855756A1 (en) * | 2011-11-29 | 2013-06-06 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of nf-kb for treatment of disease |
| WO2014205045A1 (en) * | 2013-06-18 | 2014-12-24 | Downes, Michael | Methods of treating muscular dystrophy |
| PL4023222T3 (pl) * | 2015-09-08 | 2025-03-24 | The Children's Hospital Of Philadelphia | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
| US11382922B2 (en) * | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
-
2021
- 2021-09-21 WO PCT/US2021/051274 patent/WO2022061287A1/en not_active Ceased
- 2021-09-21 JP JP2023518416A patent/JP2023543439A/ja active Pending
- 2021-09-21 MX MX2023003258A patent/MX2023003258A/es unknown
- 2021-09-21 KR KR1020237013258A patent/KR20230092905A/ko active Pending
- 2021-09-21 IL IL301500A patent/IL301500A/en unknown
- 2021-09-21 AU AU2021343534A patent/AU2021343534A1/en active Pending
- 2021-09-21 EP EP21870412.0A patent/EP4213855A4/en active Pending
- 2021-09-21 CA CA3170698A patent/CA3170698A1/en active Pending
-
2022
- 2022-02-21 US US17/651,879 patent/US20220184098A1/en not_active Abandoned
-
2023
- 2023-08-14 US US18/449,312 patent/US20240139210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| NORRIS JR et al. | The administration of guanidine in amyotrophic lateral sclerosis | |
| Lehrer et al. | Biofeedback treatment for asthma | |
| JP6768733B2 (ja) | モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 | |
| JP7153950B2 (ja) | 神経発達障害療法 | |
| LaForce et al. | Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study | |
| EP3137622B1 (en) | Methods of reducing decline in vital capacity | |
| JP2023543439A5 (https=) | ||
| JP2020002150A (ja) | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 | |
| JP2023552329A5 (https=) | ||
| Rollinson et al. | Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate | |
| EP3395341B1 (en) | Composition for treating motor neuron diseases and use thereof | |
| JP2023551009A5 (https=) | ||
| WO2007046347A1 (ja) | 筋萎縮性側索硬化症患者の運動神経保護用医薬 | |
| CN117597131A (zh) | 包含牛磺脱氧胆酸或其药学上可接受的盐作为有效成分的新型冠状病毒肺炎治疗用组合物 | |
| JP2023541007A5 (https=) | ||
| Hollow et al. | Autonomic manifestations of tetanus | |
| McLeod et al. | Intramuscular triamcinolone acetonide in chronic severe asthma. | |
| Stephan et al. | Effectiveness of Urea and of Synthetic Detergents in Reducing Activity of Human Dental Caries. | |
| JP2023554692A5 (https=) | ||
| DE69106008T2 (de) | Behandlung von Schlaf-Apnoea mit Azapironderivaten. | |
| RU2834426C2 (ru) | Способ лечения вирусных инфекций и композиция для его осуществления | |
| Anand et al. | Influence of codeine on lobeline-induced respiratory reflexes and sensations and on ventilation with exercise in healthy subjects | |
| Meade et al. | Neuropathy after thalidomide (“Distaval”) | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome |